01 9Epogen
02 2Espo
03 3NeoRecormon/Epogin
04 1Procrit
05 5Procrit/Eprex
06 2Procrit/Eprex
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 270
2018 Revenue in Millions : 297
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 598
2019 Revenue in Millions : 867
Growth (%) : -31
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 521
2020 Revenue in Millions : 598
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 266
2019 Revenue in Millions : 292
Growth (%) : -9
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 552
2019 Revenue in Millions : 790
Growth (%) : -30
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 479
2020 Revenue in Millions : 552
Growth (%) : -13
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 506
2021 Revenue in Millions : 521
Growth (%) : -3
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2015 Revenue in Millions : 2,031
2014 Revenue in Millions : 1,856
Growth (%) : -9%
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2014 Revenue in Millions : -9.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 1,096
2016 Revenue in Millions : 1,282
Growth (%) : -15
LOOKING FOR A SUPPLIER?
